newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - GUARDANT HEALTH INC

GH
  • Financial Performance:

    • Revenue drivers include 29% volume growth in Garden 360, >100% YoY growth in Reveal (MRD) tests, and >300% (3x) volume growth in SHIELD.
    • Gross margins improved significantly in Q3 due to FDA approval of low-cost, high-throughput SHIELD; COGS dropped from >$400 to $330 per test.
    • Target to reduce SHIELD COGS to $200 per test by end of 2028; automation investments expected to drive further labor cost reductions.
    • Excluding screening, the non-screening business reached breakeven in 2023 with positive cash flow; screening segment expected to reach breakeven and reduce cash burn in H2 2027.
    • Full company Free Cash Flow (FCF) break-even is targeted for Q4 2027.
    • Biopharma segment identified as the fastest-growing area, driven by data usage ($1 exabyte expected in a couple of years) and clinical trial monitoring.
  • Guidance and Future Outlook:

    • ADBL (All-Disease Blood Test) for Garden 360 FDA approval expected April 1, 2027, based on a timeline similar to SHIELD's approval cycle.
    • SHIELD sales force expansion to reach 600-700 reps (from >400 currently) to support scaling through 2027.
    • 2027 anticipated to be the year for a "sizable class" of SHIELD volumes as major payer contracts (United, Cigna, Anthem) come into effect, with United starting in August 2026 and others in Jan 2027.
    • Long-term goal involves converging MRD and therapy response monitoring markets as treatments move earlier in the disease continuum.
    • Expansion beyond oncology is planned to leverage epigenomic data for detecting 500+ non-oncology diseases (e.g., liver, kidney) in annual checkups.
  • Business Segments and Product Lines:

    • Garden 360: Continued strong performance in late-stage therapy selection; launched 11 new "smart apps" focusing on immune checkpoint inhibitors and PD-L1 blood characterization; pending FDA approval for "Liquid CDX" version expected to catalyze volume in 2027.
    • SHIELD: Launched with pharma partners; clinical launch expected by year-end; currently 83,000 tests in Q3 against a market opportunity of 18 million annual tests among 54 million unscreened patients.
    • Reveal: Growing via both standalone tissue tests and liquid MRD; new "Reveal Ultra" launched to serve both tumor-informed and tissue-free needs.
    • Biopharma & Data: Utilizing large-scale EMR and claims data to develop predictive apps and assist drug companies with early treatment response monitoring and patient segmentation using methylation/epigenomic data.
    • Channel Strategy: Prioritizing PCP (Primary Care Physician) channel expansion for non-oncology applications; DTC pilot results exceeded expectations, driving plans to reinvest gross profit into national DTC and influencer strategies.
  • Market and Competitive Landscape:

    • Market opportunity for therapy monitoring in late-stage cancer estimated at millions of tests annually due to the need for serial testing and genetic profiling at every progression.
    • Garden 360 tissue test claimed as "best-in-class" by covering genomics, transcriptomics, and methylation with low Q&S rates, driving the largest sequential tissue growth in Q3.
    • Payer penetration is critical; currently 100 million covered lives via United, Cigna, and Anthem, with reimbursement wins occurring faster than anticipated.
    • USPSCF (US Preventive Services Task Force) guideline inclusion remains a key catalyst for $0 out-of-pocket access and broad utilization, though business can grow without it currently due to existing coverage and state-level legislation.
  • Risks and Challenges:

    • Reimbursement & Policy: Dependence on USPSCF final decision (expected November) for $0 patient cost-sharing; potential friction in collection history for ASPs with new commercial payers.
    • Market Education: Need for continued physician education on new smart apps and the utility of SHIELD for breast cancer and repeat testing.
    • Operational: Automation technology for SHIELD requires FDA approval, expected late 2027, which could delay further COGS reductions.
    • Market Adoption: While DTC is performing well, widespread adoption for non-oncology diseases and the transition from tissue-only to liquid-only paradigms requires ongoing validation and market shifting.
  • Management Commentary and Tone:

    • Tone is highly confident and optimistic, describing all products as "hitting their stride" and precision medicine finally "coming to bear."
    • Management views the market as vastly underestimated, particularly regarding therapy monitoring volumes and the potential for multi-disease screening.
    • Emphasis on the "fruition" of precision oncology, leveraging hundreds of thousands of real-world data points to create new apps and clinical utilities.
    • Management expressed surprise at the speed of reimbursement wins and the strength of DTC unit economics.
  • Analyst Questions and Answers:

    • Q: Impact of new apps on revenue? A: Impacts are realized quickly; apps act like "iPhone launches" creating physician demand and new use cases.
    • Q: Tissue vs. Liquid debate? A: Strategy is to own both modalities; tissue test is comprehensive (3 legs of the stool), while liquid offers speed and serial monitoring utility.
    • Q: Therapy monitoring vs. MRD distinction? A: Short term they are linked to therapy selection; long term they converge as a unified market for patient monitoring.
    • Q: Biopharma data materiality? A: Fastest growing segment; epigenomic data provides unique utility for drugs lacking traditional genomic biomarkers and enables early efficacy reads in trials.
    • Q: FCF break-even swing factors? A: Primary drivers are ADLTA (expected to improve timeline) and SHIELD scale/COGS reduction; non-screening business is already profitable.
    • Q: USPSCF vs. Commercial Reimbursement? A: USPSCF is a major catalyst for $0 cost-sharing and quality scores, but commercial coverage is already driving significant volume and growth.
  • Other Key Points:

    • The company possesses a proprietary database of hundreds of thousands of patients with EMR, claims, and outcome data, enabling the rapid development of high-utility predictive apps.
    • The "Reveal Ultra" product targets the specific need for speed and tissue-free testing while maintaining ultra-sensitive detection capabilities.
    • State-level legislation (e.g., Pennsylvania) is successfully driving zero-cost access to SHIELD testing, providing a growth runway independent of federal USPSCF rules.
    • Management confirmed no risk regarding the Q1 2027 ADLTA timeline, citing the simplicity of the application and precedent from the SHIELD approval cycle.
Company
GUARDANT HEALTH INC
Keywords
GUARDANT HEALTH INC